RNA Formulation Articles

1. Innovations In The Oligonucleotide Supply Chain: Regulatory Considerations For Materials, Manufacturing, And Lifecycle Control 1/30/2026

   Oligonucleotide therapeutics have rapidly advanced into late-stage and commercial development, shifting regulatory focus toward the maturity of manufacturing and supply chain control rather than therapeutic novelty. Regulatory success now depends on how effectively sponsors translate innovative chemistries into well-characterized, scalable, and sustainable materials and processes.

2. The mRNA Supply Chain Revolution: Materials, Methods, And Momentum 1/30/2026

   mRNA innovation now hinges as much on manufacturing materials as on molecular design, with novel inputs shaping performance, cost, and scalability. As these less-mature materials move rapidly into production, strategic material selection and supplier alignment are becoming critical to manufacturing resilience and long-term success.

3. A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026? 1/30/2026

   In 2026, advanced therapies diverge: winners pair proven biology with scalable manufacturing, delivery, and workflow fit, while others advance more slowly under operational and economic limits.

4. 2026 Outlook: How Modality Maturity, Delivery, And Data Will Reshape RNA Therapeutics 1/28/2026

   As RNA therapeutics mature, 2026 will reward execution over novelty. Delivery, data-driven design, and modality specialization will determine which RNA platforms scale clinically and commercially.

5. Designing mRNA For The Next Generation Of Therapeutics 1/23/2026

   mRNA’s next leap goes beyond vaccines. This piece explores how tuning sequence design, structure, and longevity enables controlled protein expression for cancer, rare disease, and regenerative uses.

6. The Great Cell Therapy Reset: Solving The Industrial Math Of Living Drugs 1/15/2026

   The cell therapy sector is experiencing a paradigm shift in manufacturing: from bioreactor (ex vivo) to body (in vivo).

7. Oligonucleotide Therapeutics At Scale: Bottlenecks, Breakthroughs, And What Comes Next 1/9/2026

   Oligonucleotide therapies have proven clinical value, but scaling beyond rare disease remains hard. William Soliman, Ph.D., BCMAS, breaks down the manufacturing, delivery, and CMC realities shaping what comes next.

8. In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors 12/23/2025

   By injecting lipid-based nanoparticles encapsulating mRNA and encoding the CAR directly into the bloodstream, developers can effectively reprogram the patient's own immune cells in situ.

9. Powering Cell Therapies With RNA: A New Code For Engineered Immunity 12/19/2025

   RNA is redefining cell therapy engineering—enabling transient, programmable control of immune and stem cells while simplifying manufacturing, improving safety, and accelerating scalable, virus-free workflows.

10. Why RNA Tech Transfer Is So Hard — And How the Field Can Fix It 12/11/2025

    A closer look at why RNA tech transfer remains one of the field’s toughest bottlenecks — and the practical steps developers and CDMOs can take to finally streamline the path to GMP.